Close Menu

NEW YORK (GenomeWeb) – The litigants in an intellectual property lawsuit over liquid biopsy technology have each levied misconduct allegations against the other.

Personal Genome Diagnostics (PGDx) has alleged that Guardant Health improperly obtained at least three patents for liquid biopsy technology. And Guardant has suggested that PGDx's "infringement of the patents-in-suit is deliberate and willful and constitutes egregious misconduct."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.


Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Sponsored by

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 


This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.